GlassScriptPhysician profile
Arundhati Harati
NPI 1124085774
$12,263.45
in general payments reported to CMS, 2019-2025
45 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $1,945 · 2021: $1,681 · 2022: $1,975 · 2023: $1,903 · 2024: $1,792 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,982.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,820.00 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,186.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,005.30 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $906.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $893.05 | 2019-2025 | |
| Lilly USA, LLC | $697.62 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $667.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.74 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $412.50 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $403.87 | 2019-2023 | Steglujan, Steglatro, Belsomra |
| Amgen INC. | $387.94 | 2019-2025 | Otezla, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $366.63 | 2019-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $348.25 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $343.94 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $319.02 | 2019-2023 | Livalo, Seglentis |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arundhati Harati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.